Compare OGN & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | SGRY |
|---|---|---|
| Founded | 1923 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 2015 |
| Metric | OGN | SGRY |
|---|---|---|
| Price | $13.72 | $13.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $11.25 | ★ $18.82 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | N/A | ★ 54.14 |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $6,216,000,000.00 | $1,145,438,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $14.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $11.41 |
| 52 Week High | $13.79 | $23.44 |
| Indicator | OGN | SGRY |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 43.26 |
| Support Level | $13.46 | $13.26 |
| Resistance Level | $13.77 | $15.02 |
| Average True Range (ATR) | 0.04 | 0.79 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 59.09 | 13.95 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.